Article

Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.

Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, NE, Atlanta, GA 30322, USA.
Cell Research (Impact Factor: 11.98). 08/2008; 18(8):858-70. DOI: 10.1038/cr.2008.84
Source: PubMed

ABSTRACT Epithelial-mesenchymal transition (EMT) in cancer describes the phenotypic and behavioral changes of cancer cells from indolent to virulent forms with increased migratory, invasive and metastatic potential. EMT can be induced by soluble proteins like transforming growth factor beta1 (TGFbeta1) and transcription factors including Snail and Slug. We utilized the ARCaP(E)/ARCaP(M) prostate cancer progression model and LNCaP clones stably overexpressing Snail to identify novel markers associated with EMT. Compared to ARCaP(E) cells, the highly tumorigenic mesenchymal ARCaP(M) and ARCaP(M1) variant cells displayed a higher incidence of bone metastasis after intracardiac administration in SCID mice. ARCaP(M) and ARCaP(M1) expressed mesenchymal stromal markers of vimentin and N-cadherin in addition to elevated levels of Receptor Activator of NF-kappaB Ligand (RANKL). We observed that both epidermal growth factor (EGF) plus TGFbeta1 treatment and Snail overexpression induced EMT in ARCaP(E) and LNCaP cells, and EMT was associated with increased expression of RANKL protein. Finally, we determined that the RANKL protein was functionally active, promoting osteoclastogenesis in vitro. Our results indicate that RANKL is a novel marker for EMT during prostate cancer progression. RANKL may function as a link between EMT, bone turnover, and prostate cancer skeletal metastasis.

Download full-text

Full-text

Available from: Ruoxiang Wang, Apr 17, 2014
0 Followers
 · 
103 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HS-27a human bone stromal cells, in 2D or 3D coultures, induced cellular plasticity in human prostate cancer ARCaP(E) and ARCaP(M) cells in an EMT model. Cocultured ARCaP(E) or ARCaP(M) cells with HS-27a, developed increased colony forming capacity and growth advantage, with ARCaP(E) exhibiting the most significant increases in presence of bone or prostate stroma cells. Prostate (Pt-N or Pt-C) or bone (HS-27a) stromal cells induced significant resistance to radiation treatment in ARCaP(E) cells compared to ARCaP(M) cells. However pretreatment with anti-E-cadherin antibody (SHEP8-7) or anti-alpha v integrin blocking antibody (CNT095) significantly decreased stromal cell-induced radiation resistance in both ARCaP(E)- and ARCaP(M)-cocultured cells. Taken together the data suggest that mesenchymal-like cancer cells reverting to epithelial-like cells in the bone microenvironment through interaction with bone marrow stromal cells and reexpress E-cadherin. These cell adhesion molecules such as E-cadherin and integrin alpha v in cancer cells induce cell survival signals and mediate resistance to cancer treatments such as radiation.
    Journal of Oncology 07/2010; 2010. DOI:10.1155/2010/232831
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is one of the most common solid tumors affecting men. Localized stages can be cured, however, once disseminated to distant organs the median survival drops below 12months. The challenge for the future consists of unifying gained insights of cellular signal dysfunctioning (“theragates”) with the knowledge of disease detection (“theragnostics”) in personalized therapy. In solid malignancies, multiple signal transduction molecules are often deregulated simultaneously, within the same tumor. A multi-targeted approach may possibly improve efficacy, but will also increase toxicity, thus, potentially limiting the use of various combinations. On the other hand, well-established treatment modalities in prostate cancer, such as radiotherapy with its known efficacy and limited toxicity, may be an attractive combination partner for protein kinase inhibitors. Deregulation of the epidermal growth factor receptor (EGFR) signal transduction pathway is observed in a variety of solid tumors, including prostate cancer. Furthermore, one important DNA repair mechanism is dependent on EGFR nuclear translocation, thus, providing a rationale for combining radiotherapy with EGFR inhibitors. This article reviews current knowledge regarding this combination paradigm, revealing an intriguing therapy option to be explored for patients with advanced prostate cancer. KeywordsProstate cancer–EGF–HER2–Radiotherapy–Theragnostics–Theragates
    Oncology Reviews 06/2011; 5(2):119-128. DOI:10.1007/s12156-010-0070-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reciprocal cellular interactions between cancer and host allow cancer cells to gain increased growth and survival advantages (1, 2). This relationship exists between prostate cancer and bone in which prostate cancer cells are shown to exhibit osteomimicry, or bone-like properties, by expressing osteocalcin (OC) and bone sialoprotein (BSP). We found a soluble factor, �2-Microglobulin ( �2-M), is responsible for the activation CREB via PKA, which promotes OC and BSP transcription and translation (3-5). �2-M overexpression in prostate cancer cells promotes Epithelial to Mesenchymal Transition (EMT) in an ARCaP model of human prostate cancer and drives these cells toward mouse bone (6, 7). Similar observations were demonstrated in human breast, lung and renal cancer cells supporting the concept a common functional role of �2-M which is capable of accelerating human cancer bone metastases. Since �2-M has been shown to be a prognostic factor and a therapeutic target for human multiple myeloma (8, 9), we and others also provided evidence that �2-M is a diagnostic, prognostic and treatment target for human prostate cancer (3, 10-12). In our recent studies, we provided evidence that a putative �2-M receptor, a hereditary hemochromatosis associated gene, HFE, known also as a major histocompatibility complex (MHC) class I-like molecule, responded to �2-M, and induced EMT by modulating iron homeostasis in prostate cancer cells. We will discuss how these series of investigations led to the understanding of the pleiotropic cell signaling roles of �2-M and the participation of oxidative stress in prostate cancer bone metastasis. Our results also revealed targeting �2-M-mediated cell signaling network can be achieved through modulation of iron homeostatsis. These results predict synergistic interaction between anti-�2-M antibody and chemotherapy or radiation in experimental models of human cancer metastases.